Johnson & Johnson $JNJ Shares Purchased by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. raised its stake in Johnson & Johnson (NYSE:JNJ) by 6.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,625 shares of the company’s stock after purchasing an additional 542 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Johnson & Johnson were worth $1,317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. GFG Capital LLC purchased a new position in Johnson & Johnson in the second quarter worth approximately $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the first quarter valued at $52,000. Finally, Pandora Wealth Inc. purchased a new position in Johnson & Johnson in the first quarter valued at $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.8%

Shares of Johnson & Johnson stock opened at $199.39 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $480.38 billion, a P/E ratio of 19.25, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $200.28. The company’s fifty day moving average is $186.24 and its two-hundred day moving average is $170.46.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on JNJ shares. UBS Group upped their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.